Results of Operations and Financial Condition. On August 13, 2026, Eikon Therapeutics, Inc. issued a press release announcing clinical and corporate updates and its financial results for the quarter ended June 30, 2026 (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Item 2.02, including Exhibit 99.1, is being “furnished” and shall not be deemed to be “filed” for purpo…

Director — Leon Chen, Ph.D. and Joshua Wolfe: Dr. Leon Chen and Mr. Joshua Wolfe resigned from the Board of Directors without a stated successor.

Class I director — Ma. Fatima D. Francisco: Ms. Francisco was appointed to the Board of Directors as a Class I director.

Results of Operations and Financial Condition. On May 11, 2026, Eikon Therapeutics, Inc. (the "Company") issued a press release announcing clinical and corporate updates and its financial results for the quarter ended March 31, 2026 (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Results of Operations and Financial Condition. On March 30, 2026, Eikon Therapeutics, Inc. issued a press release announcing clinical and corporate updates and its financial results for the three months and full year ended December 31, 2025 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1 and is incorporated by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, is being “furnished” and shall not be deemed to be “filed” for purp…